NCT02002598 : Phase 1 /2 -Carfilzomib + Bendamustine and Dex in New MM
Updated: Mar 28, 2022
This study is designed to define dose-limiting toxicity and determine preliminary evidence of efficacy of Carfilzomib (CFZ) in combination with bendamustine and dexamethasone for patients with newly diagnosed multiple myeloma (MM).
ClinicalTrials.gov Identifier: NCT02002598
Blood Cancer J : Feb 3, 2020